^
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5d
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=330, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Jun 2027
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    6d
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    6d
    Immune checkpoint therapy in pediatric and adolescent lymphomas. (PubMed, Haematologica)
    In PMBCL, the Children's Oncology Group (COG) and the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) recently completed a randomized phase III trial of nivolumab in combination with chemo-immunotherapy in children and adults with newly diagnosed PMBCL...In ALCL and ANKL, ongoing clinical trials are evaluating the efficacy of ICT. Given the transformational role of ICT for pediatric Hodgkin lymphoma, there is significant promise for the use of ICT in multiple subtypes of pediatric non-Hodgkin lymphoma with increased expression of PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    7d
    Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
    New trial
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin)
    8d
    Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas (clinicaltrials.gov)
    P2, N=25, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Copiktra (duvelisib) • ETP-47187
    8d
    Expression of GATA3 in Patients with Peripheral T-Cell Lymphoma and Its Clinical Significance (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The GATA3 gene is closely associated with the prognosis of patients with PTCL. Patients with high expression of GATA3 may have a poorer prognosis.
    Journal
    |
    GATA3 (GATA binding protein 3)
    8d
    Secondary cutaneous involvement in peripheral T-cell lymphoma: Diagnostic frameworks, staging integration, and therapeutic implications. (PubMed, J Investig Med)
    Treatment with brentuximab vedotin yielded early alleviation of pruritus and progressive resolution of lesions by the third cycle, with favorable tolerability. This case serves as a foundation for a narrative review that underscores the diagnostic challenges associated with "allergic-appearing" eruptions in patients with T-cell lymphoma, the importance of integrated staging utilizing TNMB (skin/blood) in conjunction with Lugano/Deauville positron emission tomography-computed tomography to assess systemic burden and therapeutic response, and biologically informed systemic therapy options aligned with comorbidities, including emerging targeted treatment strategies.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • TRB (T Cell Receptor Beta Locus)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    12d
    Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab)
    12d
    Oral manifestations of anaplastic large cell lymphoma: clinicopathological features and main immunophenotypic findings of 3 cases. (PubMed, J Hematop)
    One patient was known to decease despite chemotherapy. In conclusion, oral manifestations of ALCL are very rare and more commonly represent a disseminated disease.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression • ALK negative
    15d
    Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Keytruda (pembrolizumab) • Folotyn (pralatrexate)
    16d
    Unmasking peripheral T-cell lymphoma in dermatomyositis with anti-PM/Scl-100 and anti-Mi-2 positivity: a case-based review. (PubMed, Rheumatol Int)
    She was diagnosed with DM and treated with oral prednisolone...These cases suggest that repeat tissue evaluation, particularly of skin lesions, may be critical in atypical or treatment-refractory cases. Our case highlights that even a DM phenotype with autoantibodies generally considered less strongly associated with malignancy does not exclude occult lymphoma in elderly patients.
    Review • Journal
    |
    IL2 (Interleukin 2)
    |
    prednisolone